SCHEMBL17875680

SCHEMBL17875680

Cc1nc2c(Br)cc(Br)cc2n1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.46
PRNP P04156 3/20 0.41
LMNA P02545 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41
NOD2 Q9HC29 1/20 0.41
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
KDM4E B2RXH2 1/20 0.38
NQO2 P16083 2/20 0.35
GRM2 Q14416 1/20 0.35
HSD17B10 Q99714 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25105335 0.85 NQO2 (0.41) EGFRLMNAMAPTALDH1A1KDM4E
SCHEMBL21539307 0.81 ACACB (0.39) EGFRLMNAHTTMAPTALDH1A1
SCHEMBL4664776 0.81 EGFR (0.37) EGFRLMNAHTTMAPTALDH1A1
SCHEMBL4664889 0.75 LMNA (0.40) EGFRLMNANPSR1HTTMAPT
SCHEMBL25849486 0.73 KDM4E (0.34) LMNAALDH1A1KDM4ECYP1A2CYP3A4
SCHEMBL21820452 0.73 LMNA (0.46) LMNANPSR1MAPTALDH1A1RXFP1
SCHEMBL24745509 0.73 LMNA (0.41) LMNAHPGDMAPTALDH1A1KDM4E
SCHEMBL4777017 0.73 NPC1 (0.34) EGFRLMNAHPGDHTTMAPT
SCHEMBL34471790 0.73 KDM4E (0.35) EGFRLMNAMAPTALDH1A1KDM4E
SCHEMBL17875676 0.71 BRD4 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9999616-B2 2018-06-19 US disclosed
US-20170216257-A1 NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS RVX THERAPEUTICS INC. (CA) 2017-08-03 US disclosed
US-9662311-B2 Substituted bicyclic compounds as bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2017-05-30 US disclosed
US-20160184273-A1 NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS ZENITH EPIGENETICS CORP. (CA) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160184273-A1 NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 EGFR 1232/4885PRNP 3048/4885LMNA 2533/4885
US-20170216257-A1 NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS BRD4, BRD3, BRD2 EGFR 1232/4885PRNP 3048/4885LMNA 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.